

DIN EN ISO 10993-11:2018-09 (E)

Biological evaluation of medical devices - Part 11: Tests for systemic toxicity (ISO 10993-11:2017)

Contents	Page
European foreword.....	4
Endorsement notice.....	5
Annex ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered.....	6
Annex ZB (informative) Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered.....	8
Foreword.....	10
Introduction.....	11
1 Scope.....	12
2 Normative references.....	12
3 Terms and definitions.....	12
4 General considerations.....	14
4.1 General.....	14
4.2 Selection of animal species.....	14
4.3 Animal status.....	14
4.4 Animal care and husbandry.....	14
4.5 Size and number of groups.....	15
4.5.1 Size of groups.....	15
4.5.2 Number of groups.....	15
4.5.3 Treatment controls.....	15
4.6 Route of exposure.....	16
4.7 Sample preparation.....	16
4.8 Dosing.....	16
4.8.1 Test sample administration.....	16
4.8.2 Dosage volumes.....	16
4.8.3 Dosage frequency.....	17
4.9 Body weight and food/water consumption.....	17
4.10 Clinical observations.....	17
4.11 Clinical pathology.....	17
4.12 Anatomic pathology.....	18
4.13 Study designs.....	18
4.14 Quality of investigation.....	18
5 Acute systemic toxicity.....	18
5.1 General.....	18
5.2 Study design.....	19
5.2.1 Preparations.....	19
5.2.2 Experimental animals.....	19
5.2.3 Test conditions.....	19
5.2.4 Body weights.....	20
5.2.5 Clinical observations.....	20
5.2.6 Pathology.....	20
5.3 Evaluation criteria.....	21
5.3.1 General.....	21
5.3.2 Evaluation of results.....	21
5.4 Final report.....	21

6	Repeated exposure systemic toxicity (subacute, subchronic and chronic systemic toxicity)	23
6.1	General	23
6.2	Study design	23
	6.2.1 Preparations	23
	6.2.2 Experimental animals	23
	6.2.3 Test conditions	24
	6.2.4 Body weights	24
	6.2.5 Clinical observations	24
	6.2.6 Pathology	24
6.3	Evaluation criteria	25
	6.3.1 General	25
	6.3.2 Evaluation of results	25
6.4	Final report	26
	Annex A (informative) Routes of administration	27
	Annex B (informative) Dosage volumes	29
	Annex C (informative) Common clinical signs and observations	30
	Annex D (informative) Suggested haematology, clinical chemistry and urinalysis measurements	31
	Annex E (informative) Suggested organ list for histopathological evaluation	33
	Annex F (informative) Organ list for limited histopathology for medical devices subjected to systemic toxicity testing	35
	Annex G (informative) Information on material-mediated pyrogens	36
	Annex H (informative) Subchronic rat — Dual routes of parenteral administration	37
	Bibliography	39